A Cost-Utility Analysis of Pregabalin Versus Duloxetine for the Treatment of Painful Diabetic Neuropathy

REFERENCES

• Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2011.
   Google Scholar
• Boulton AJ, Vinik AI, Arezzo JC, Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care. 2005;28:956–962.
   PubMed Web of Science ®Google Scholar
• Woolf CJ, Mannion RJ. Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet. 1999;353: 1959–1964.
   PubMed Web of Science ®Google Scholar
• Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain. 2002;18:350–354.
   PubMed Web of Science ®Google Scholar
• Partanen J, Niskanen L, Lehtinen J, Mervaala E, Siitonen O, Uusitupa M. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1995; 333:89–94.
   PubMed Web of Science ®Google Scholar
• Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia. 1993;36:150–154.
   PubMed Web of Science ®Google Scholar
• Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract. 2000;47:123–128.
   PubMed Web of Science ®Google Scholar
• Benbow SJ, Wallymahmed ME, MacFarlane IA. Diabetic peripheral neuropathy and quality of life. QJM. 1998;91:733–737.
   PubMed Web of Science ®Google Scholar
• Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care. 2003;26:1790–1795.
   PubMed Web of Science ®Google Scholar
• Bril V, England J, Franklin GM, Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. PM R. 2011;3:345–352.
   PubMedGoogle Scholar
• Lyrica Prescribing Information. New York, NY: Pfizer, Inc; 2011.
   Google Scholar
• Cymbalta Prescribing Information. Indianapolis, IN: Eli Lilly and Company; 2011.
   Google Scholar
• O'Connor AB, Noyes K, Holloway RG. A cost-utility comparison of four first-line medications in painful diabetic neuropathy. Pharmacoeconomics. 2008;26:1045–1064.
   PubMed Web of Science ®Google Scholar
• Cepeda MS, Farrar JT. Economic evaluation of oral treatments for neuropathic pain. J Pain. 2006;7:119–128.
   PubMed Web of Science ®Google Scholar
• O'Connor AB, Noyes K, Holloway RG. A cost-effectiveness comparison of desipramine, gabapentin, and pregabalin for treating postherpetic neuralgia. J Am Geriatr Soc. 2007;55: 1176–1184.
   PubMed Web of Science ®Google Scholar
• Arezzo JC, Rosenstock J, Lamoreaux L, Pauer L. Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. BMC Neurol. 2008;8:33.
   PubMed Web of Science ®Google Scholar
• Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain. 2005;115:254–263.
   PubMed Web of Science ®Google Scholar
• Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology. 2004;63:2104–2110.
   PubMed Web of Science ®Google Scholar
• PhRMA Web synopsis from Pfizer. Protocol No. 1008-040: A Placebo-Controlled Trial of Pregabalin and Amitriptyline for Treatment of Painful Diabetic Peripheral Neuropathy. 2007. Available at: http://www.clinicalstudyresults.org/drugdetails/?drug_name_id=203&sort=c.company_name&page=2&drug_id=1952. Accessed November 15, 2011.
   Google Scholar
• Richter RW, Portenoy R, Sharma U, Lamoreaux L, Bockbrader H, Knapp LE. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain. 2005;6:253–260.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain. 2004;110: 628–638.
   PubMed Web of Science ®Google Scholar
• Stacey BR, Dworkin RH, Murphy K, Sharma U, Emir B, Griesing T. Pregabalin in the treatment of refractory neuropathic pain: results of a 15-month open-label trial. Pain Med. 2008;9:1202–1208.
   PubMed Web of Science ®Google Scholar
• Tanenberg RJ, Irving GA, Risser RC, Duloxetine, pregabalin, and duloxetine plus gabapentin for diabetic peripheral neuropathic pain management in patients with inadequate pain response to gabapentin: an open-label, randomized, noninferiority comparison. Mayo Clin Proc. 2011;86:615–626.
   PubMed Web of Science ®Google Scholar
• Tolle T, Freynhagen R, Versavel M, Trostmann U, Young JP Jr. Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur J Pain. 2008;12:203–213.
   PubMed Web of Science ®Google Scholar
• Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005;116:109–118.
   PubMed Web of Science ®Google Scholar
• Raskin J, Pritchett YL, Wang F, A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med. 2005;6:346–356.
   PubMed Web of Science ®Google Scholar
• Raskin J, Smith TR, Wong K, Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain. J Palliat Med. 2006;9:29–40.
   PubMed Web of Science ®Google Scholar
• Raskin J, Wang F, Pritchett YL, Goldstein DJ. Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study. Pain Med. 2006;7:373–385.
   PubMed Web of Science ®Google Scholar
• Wernicke JF, Pritchett YL, D'Souza DN, A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology. 2006;67:1411–1420.
   PubMed Web of Science ®Google Scholar
• Wernicke JF, Wang F, Pritchett YL, An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain. Pain Med. 2007;8:503–513.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Sun P, Watson P. Medication adherence and healthcare costs among patients with diabetic peripheral neuropathic pain initiating duloxetine versus pregabalin. Curr Med Res Opin. 2011;27:785–792.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Sun P, Watson P, Mitchell B, Swindle R. Comparison of medication adherence and healthcare costs between duloxetine and pregabalin initiators among patients with fibromyalgia. Pain Pract. 2011;11:204–216.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Wu N, Chen S, Boulanger L, Police RL, Fraser K. Changes in opioid use and healthcare costs among U.S. patients with diabetic peripheral neuropathic pain treated with duloxetine compared with other therapies. Curr Med Res Opin. 2010;26:2147–2156.
   PubMed Web of Science ®Google Scholar
• Chen S, Wu N, Fraser K, Boulanger L, Zhao Y. Opioid use and healthcare costs among patients with DPNP initiating duloxetine versus other treatments. Curr Med Res Opin. 2010;26:2507–2516.
   PubMed Web of Science ®Google Scholar
• Wu N, Chen SY, Hallett LA, Opioid utilization and health-care costs among patients with diabetic peripheral neuropathic pain treated with duloxetine vs. other therapies. Pain Pract. 2011;11:48–56.
   Google Scholar
• Gore M, Tai KS, Zlateva G, Bala Chandran A, Leslie D. Clinical characteristics, pharmacotherapy, and healthcare resource use among patients with diabetic neuropathy newly prescribed pregabalin or gabapentin. Pain Pract. 2011;11:528–539.
   PubMed Web of Science ®Google Scholar
• Gore M, Zlateva G, Tai KS, Chandran AB, Leslie D. Retrospective evaluation of clinical characteristics, pharmacotherapy and healthcare resource use among patients prescribed pregabalin or duloxetine for diabetic peripheral neuropathy in usual care. Pain Pract. 2011;11:167–179.
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Panarites CJ, Armstrong EP, Malone DC, Pham SV. Healthcare utilization in people with postherpetic neuralgia and painful diabetic peripheral neuropathy. J Am Geriatr Soc. 2011;59:827–836.
   PubMed Web of Science ®Google Scholar
• Micromedex® 2.0. RED BOOK Online®. Available at: http://www.thomsonhc.com/micromedex2/librarian. Accessed December 6, 2011.
   Google Scholar
• US Department of Labor, Bureau of Labor Statistics. Consumer Price Index. Available at: http://www.bls.gov/cpi/home.htm. Accessed December 15, 2011.
   Google Scholar
• Gore M, Brandenburg NA, Dukes E, Hoffman DL, Tai KS, Stacey B. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manage. 2005;30:374–385.
   PubMed Web of Science ®Google Scholar
• Brooks R. EuroQol: the current state of play. Health Policy. 1996;37:53–72.
   PubMed Web of Science ®Google Scholar
• Wilby J, Kainth A, Hawkins N, Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. Health Technol Assess. 2005;9:1–157, iii–iv.
   PubMed Web of Science ®Google Scholar
• Nicholson T, McGuire A, Milne R. Cost-utility of enoxaparin compared with unfractionated heparin in unstable coronary artery disease. BMC Cardiovasc Disord. 2001;1:2.
   PubMedGoogle Scholar
• Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 2000;17:479–500.
   PubMed Web of Science ®Google Scholar
• Nayak S, Roberts MS, Greenspan SL. Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women. Ann Intern Med. 2011;155:751–761.
   PubMed Web of Science ®Google Scholar
• Holmes KP, Fang JC, Jackson BR. Cost-effectiveness of six strategies for Helicobacter pylori diagnosis and management in uninvestigated dyspepsia assuming a high resource intensity practice pattern. BMC Health Serv Res. 2010;10:344.
   Google Scholar
• Spiegel BM, Targownik L, Dulai GS, Gralnek IM. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Ann Intern Med. 2003;138:795–806.
   PubMed Web of Science ®Google Scholar
• Beard SM, McCrink L, Le TK, Garcia-Cebrian A, Monz B, Malik RA. Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK. Curr Med Res Opin. 2008;24:385–399.
   PubMed Web of Science ®Google Scholar
• Wu EQ, Birnbaum HG, Mareva MN, Cost-effectiveness of duloxetine versus routine treatment for U.S. patients with diabetic peripheral neuropathic pain. J Pain. 2006;7:399–407.
   PubMed Web of Science ®Google Scholar
• Braithwaite RS, Meltzer DO, King JT, Jr., Leslie D, Roberts MS. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care. 2008;46:349–356.
   PubMed Web of Science ®Google Scholar
• Gore M, Brandenburg NA, Hoffman DL, Tai KS, Stacey B. Burden of illness in painful diabetic peripheral neuropathy: the patients’ perspectives. J Pain. 2006;7:892–900.
   PubMed Web of Science ®Google Scholar